| Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy M van Putten, K Putker, M Overzier, WA Adamzek, S Pasteuning-Vuhman, ... The FASEB Journal 33 (7), 8110, 2019 | 134 | 2019 |
| Towards advanced iPSC-based drug development for neurodegenerative disease S Pasteuning-Vuhman, R de Jongh, A Timmers, RJ Pasterkamp Trends in molecular medicine 27 (3), 263-279, 2021 | 53 | 2021 |
| Neuromuscular junctiononachip: ALS disease modeling and readout development in microfluidic devices R de Jongh, XM Spijkers, S PasteuningVuhman, P Vulto, RJ Pasterkamp Journal of neurochemistry 157 (3), 393-412, 2021 | 45 | 2021 |
| A directional 3D neurite outgrowth model for studying motor axon biology and disease XM Spijkers, S Pasteuning-Vuhman, JC Dorleijn, P Vulto, NR Wevers, ... Scientific reports 11 (1), 2080, 2021 | 42 | 2021 |
| New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration S Pasteuning-Vuhman, JW Boertje-van der Meulen, M Van Putten, ... The FASEB Journal 31 (1), 238, 2017 | 37 | 2017 |
| Targeting TGF-β signaling by antisense oligonucleotide-mediated knockdown of TGF-β type I receptor DU Kemaladewi, S Pasteuning, JW Van Der Meulen, SH Van Heiningen, ... Molecular Therapy-Nucleic Acids 3, 2014 | 36 | 2014 |
| Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F S Pasteuning-Vuhman, K Putker, CL Tanganyika-de Winter, ... PloS one 12 (8), e0182704, 2017 | 24 | 2017 |
| Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F IEC Verhaart, K Putker, D van de Vijver, CL Tanganyika-de Winter, ... PLoS One 14 (8), e0220665, 2019 | 17 | 2019 |
| Efficient Downregulation of Alk4 in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy S Engelbeen, S Pasteuning-Vuhman, J Boertje-van der Meulen, ... nucleic acid therapeutics 33 (1), 26-34, 2023 | 10 | 2023 |
| Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy S Pasteuning-Vuhman, K Putker, CL Tanganyika-de Winter, ... PloS one 13 (5), e0197388, 2018 | 10 | 2018 |
| What We Have Learned from 10 Years of DMD Exon-Skipping Trials S Pasteuning-Vuhman, A Aartsma-Rus Muscle Gene Therapy, 745-758, 2019 | 1 | 2019 |
| Amyotrophic Lateral Sclerosis Proteomic Signature And Treatment With Mesenchymal Stem Cell-derived Extracellular Vesicles S Varderidou-Minasian, S Pasteuning-Vuhman, A Timmers, M Altelaar, ... bioRxiv, 2022.07. 05.498816, 2022 | | 2022 |
| Meulen S Engelbeen, S Pasteuning-Vuhman B. an der, Parmar, R., Charisse, K., Sepp-Lorenzino, L.,… Putten, M. an, 2022 | | 2022 |
| To ards therapies for muscular d strophies: targeting TGF-beta and m ostatin signalling to impro e muscle qualit and de elopment of reliable outcome measures for preclinical … S Pasteuning-Vuhman | | 2018 |
| TOWARDS THERAPIES FOR MUSCULAR DYSTROPHIES S Pasteuning-Vuhman | | 2018 |
| GENE EXPRESSION PROFILING OF KEY PATHOLOGICAL PATHWAYS IN UTROPHIN/DYSTROPHIN-DEFICIENT AND MDX MUSCLES S Pasteuning-Vuhman, T McDonald, S Guirten, M Overzier, ... | | 2018 |
| Towards therapies for muscular dystrophies: targeting TGF-beta and myostatin signalling to improve muscle quality and development of reliable outcome measures for preclinical … S Pasteuning-Vuhman Leiden University, 2018 | | 2018 |
| New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration S Pasteuning, J Boertje–van der Meulen, M van Putten, M Overzier, ... Neuromuscular Disorders 26, S153, 2016 | | 2016 |
